Elan Fourth-Quarter Losses Narrow as Tysabri Sales Grow
CNBC - Englewood Cliffs,NJ,USA
Tysabri, Elan's key product developed in conjunction with US drug maker Biogen Idec, was withdrawn from US sale shortly after its launch in February 2005 ...
See all stories on this topic

Tysabri forecast to drive Elan's return to profitability
Pharma Times (subscription) - London,UK
Ireland's Elan Corp has posted a reduction in losses for the fourth quarter and says that its mutiple sclerosis drug multiple sclerosis treatment Tysabri ...
See all stories on this topic

Elan CFO: Tysabri could post revenue over $300 mln in 2007
MarketWatch - USA
PLC's (ELN) chief financial officer said Tuesday that, based on the current patient take-up, its multiple sclerosis drug Tysabri could make more than $300 ...
See all stories on this topic

Elan quarterly loss narrows, sees return to profit
MarketWatch - USA
However, Elan also said that 2007 revenues excluding Tysabri should exceed $500 million, with research and development and SG&A expenses to be in the range ...
See all stories on this topic